Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia
Background: Cytogenetics at diagnosis is the most important prognostic factor for adult acute myeloid leukemia (AML), but nearly 50% of AML patients who exhibit cytogenetically normal AML (CN-AML) do not undergo effective risk stratification. Therefore, the development of potential biomarkers to fur...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-11-01
|
| Series: | Technology in Cancer Research & Treatment |
| Online Access: | https://doi.org/10.1177/15330338211052152 |
| _version_ | 1818403915729731584 |
|---|---|
| author | Cunte Chen MD Zhuowen Chen MD Chi Leong Chio MD Ying Zhao MD Yongsheng Li MM Zhipeng Liu MM Zhenyi Jin MD Xiuli Wu MD Wei Wei PhD Qi Zhao PhD Yangqiu Li MD |
| author_facet | Cunte Chen MD Zhuowen Chen MD Chi Leong Chio MD Ying Zhao MD Yongsheng Li MM Zhipeng Liu MM Zhenyi Jin MD Xiuli Wu MD Wei Wei PhD Qi Zhao PhD Yangqiu Li MD |
| author_sort | Cunte Chen MD |
| collection | DOAJ |
| description | Background: Cytogenetics at diagnosis is the most important prognostic factor for adult acute myeloid leukemia (AML), but nearly 50% of AML patients who exhibit cytogenetically normal AML (CN-AML) do not undergo effective risk stratification. Therefore, the development of potential biomarkers to further define risk stratification for CN-AML patients is worth exploring. Methods: Transcriptome data from 163 cases in the GSE12417-GPL96 dataset and 104 CN-AML patient cases in the GSE71014-GPL10558 dataset were downloaded from the Gene Expression Omnibus database for overall survival (OS) analysis and validation. Results: The combination of Wilms tumor 1 ( WT1 ) and cluster of diffraction 58 ( CD58 ) can predict the prognosis of CN-AML patients. High expression of WT1 and low expression of CD58 were associated with poor OS in CN-AML. Notably, when WT1 and CD58 were used to concurrently predict OS, CN-AML patients were divided into three groups: low risk, WT1 low CD58 high ; intermediate risk, WT1 high CD58 high or WT1 low CD58 low ; and high risk, WT1 high CD5 8 low . Compared with low-risk patients, intermediate- and high-risk patients had shorter survival time and worse OS. Furthermore, a nomogram model constructed with WT1 and CD58 may personalize and reveal the 1-, 2-, 3-, 4-, and 5-year OS rate of CN-AML patients. Both time-dependent receiver operating characteristics and calibration curves suggested that the nomogram model demonstrated good performance. Conclusion: Higher expression of WT1 with lower CD58 expression may be a potential biomarker for risk stratification of CN-AML patients. Moreover, a nomogram model constructed with WT1 and CD58 may personalize and reveal the 1-, 2-, 3-, 4-, and 5-year OS rates of CN-AML patients. |
| first_indexed | 2024-12-14T08:31:51Z |
| format | Article |
| id | doaj.art-a692c929daee4ec78762d83b04da202e |
| institution | Directory Open Access Journal |
| issn | 1533-0338 |
| language | English |
| last_indexed | 2024-12-14T08:31:51Z |
| publishDate | 2021-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Technology in Cancer Research & Treatment |
| spelling | doaj.art-a692c929daee4ec78762d83b04da202e2022-12-21T23:09:31ZengSAGE PublishingTechnology in Cancer Research & Treatment1533-03382021-11-012010.1177/15330338211052152Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid LeukemiaCunte Chen MD0Zhuowen Chen MD1Chi Leong Chio MD2Ying Zhao MD3Yongsheng Li MM4Zhipeng Liu MM5Zhenyi Jin MD6Xiuli Wu MD7Wei Wei PhD8Qi Zhao PhD9Yangqiu Li MD10 Institute of Hematology, School of Medicine, , Guangzhou, China , Foshan, China Institute of Hematology, School of Medicine, , Guangzhou, China , Foshan, China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd, Guangzhou, Guangdong, China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd, Guangzhou, Guangdong, China Institute of Hematology, School of Medicine, , Guangzhou, China Institute of Hematology, School of Medicine, , Guangzhou, China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd, Guangzhou, Guangdong, China Institute of Translational Medicine, Cancer Centre, , Taipa, Macau SPR, China Institute of Hematology, School of Medicine, , Guangzhou, ChinaBackground: Cytogenetics at diagnosis is the most important prognostic factor for adult acute myeloid leukemia (AML), but nearly 50% of AML patients who exhibit cytogenetically normal AML (CN-AML) do not undergo effective risk stratification. Therefore, the development of potential biomarkers to further define risk stratification for CN-AML patients is worth exploring. Methods: Transcriptome data from 163 cases in the GSE12417-GPL96 dataset and 104 CN-AML patient cases in the GSE71014-GPL10558 dataset were downloaded from the Gene Expression Omnibus database for overall survival (OS) analysis and validation. Results: The combination of Wilms tumor 1 ( WT1 ) and cluster of diffraction 58 ( CD58 ) can predict the prognosis of CN-AML patients. High expression of WT1 and low expression of CD58 were associated with poor OS in CN-AML. Notably, when WT1 and CD58 were used to concurrently predict OS, CN-AML patients were divided into three groups: low risk, WT1 low CD58 high ; intermediate risk, WT1 high CD58 high or WT1 low CD58 low ; and high risk, WT1 high CD5 8 low . Compared with low-risk patients, intermediate- and high-risk patients had shorter survival time and worse OS. Furthermore, a nomogram model constructed with WT1 and CD58 may personalize and reveal the 1-, 2-, 3-, 4-, and 5-year OS rate of CN-AML patients. Both time-dependent receiver operating characteristics and calibration curves suggested that the nomogram model demonstrated good performance. Conclusion: Higher expression of WT1 with lower CD58 expression may be a potential biomarker for risk stratification of CN-AML patients. Moreover, a nomogram model constructed with WT1 and CD58 may personalize and reveal the 1-, 2-, 3-, 4-, and 5-year OS rates of CN-AML patients.https://doi.org/10.1177/15330338211052152 |
| spellingShingle | Cunte Chen MD Zhuowen Chen MD Chi Leong Chio MD Ying Zhao MD Yongsheng Li MM Zhipeng Liu MM Zhenyi Jin MD Xiuli Wu MD Wei Wei PhD Qi Zhao PhD Yangqiu Li MD Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia Technology in Cancer Research & Treatment |
| title | Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia |
| title_full | Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia |
| title_fullStr | Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia |
| title_full_unstemmed | Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia |
| title_short | Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia |
| title_sort | higher expression of with lower expression may be biomarkers for risk stratification of patients with cytogenetically normal acute myeloid leukemia |
| url | https://doi.org/10.1177/15330338211052152 |
| work_keys_str_mv | AT cuntechenmd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT zhuowenchenmd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT chileongchiomd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT yingzhaomd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT yongshenglimm higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT zhipengliumm higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT zhenyijinmd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT xiuliwumd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT weiweiphd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT qizhaophd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia AT yangqiulimd higherexpressionofwithlowerexpressionmaybebiomarkersforriskstratificationofpatientswithcytogeneticallynormalacutemyeloidleukemia |